<DOC>
	<DOCNO>NCT02794467</DOCNO>
	<brief_summary>The primary objective study ass efficacy , safety , tolerability epelsiban compare placebo treatment woman adenomyosis . This 12-week , randomize , double-blind , placebo-controlled , parallel group study interim futility analysis . Subjects randomize 1:1:1 receive 75 milligram ( mg ) epelsiban three time daily ( TID ) , 200 mg epelsiban TID , placebo TID . The study compose three period : screening , treatment , follow-up total time subject study approximately 6 month .</brief_summary>
	<brief_title>Placebo-controlled Proof Concept Study Epelsiban Women With Adenomyosis</brief_title>
	<detailed_description />
	<mesh_term>Adenomyosis</mesh_term>
	<mesh_term>Diketopiperazines</mesh_term>
	<criteria>Eighteen 55 year age , inclusive Premenopausal history regular menstrual cycle every 2135 day without intermenstrual bleeding heavier spot stain . Females adenomyosis confirm magnetic resonance imaging ( MRI ) , Females heavy menstrual bleeding . Willing able collect menstrual cycle byproduct cycle screen follow . Not pregnant confirm negative serum human chorionic gonadotropin A female subject eligible inclusion study follow criterion apply : Abnormal gynecological examination adenomyosis and/or breast examination require intervention within six month study start Abnormal endometrial biopsy within six month start study treatment . History endometrial ablation within 12 month start study treatment . Uterine artery embolization within six month start study treatment . Prior major uterine procedure significant uterine abnormality MRI ( previous caesarean section , dilation curettage , diagnostic hysteroscopy permit ) . Confirmed rectovaginal endometriosis woman undergone prior laparoscopy . Active pelvic infection current use intrauterine device within three month screen . Women history transfusion heavy menstrual bleeding within past 2 year history postpartum hemorrhage . Any uterine dimension &gt; 20 centimeter ( cm ) . Other major cause heavy menstrual bleeding Use within 3 month anticipate use medication modify reproductive function Use anticipate use follow drug : anticoagulant aminocaproic acid , medication affect menstrual bleeding tranexamic acid . Use daily opioid pain medication menses . Hemoglobin &lt; 8 gram ( g ) /deciliter . History bleed disorder know presence acquire inherited thrombophilia , ( sickle cell trait individual exclude ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heavy menstrual bleeding</keyword>
	<keyword>Adenomyosis</keyword>
	<keyword>Safety</keyword>
	<keyword>Epelsiban</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Proof concept</keyword>
</DOC>